Consolidated Balance Sheets - USD ($) $ in Millions		Mar. 31, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents		$ 1,743	$ 2,177
Accounts receivables, net of allowance for credit losses of $119 million and $126 million as of March 31, 2021 and December 31, 2020		4,572	4,581
Inventories		4,406	4,403
Prepaid expenses		942	945
Other current assets		652	710
Assets held for sale		87	189
Total current assets		12,401	13,005
Deferred income taxes		691	695
Other non-current assets		524	538
Property, plant and equipment, net		6,112	6,296
Operating lease right-of-use assets		529	559
Identifiable intangible assets, net		8,445	8,923
Goodwill	[1]	20,302	20,624
Total assets		49,004	50,640
Current liabilities:
Short-term debt		2,697	3,188
Sales reserves and allowances		4,584	4,824
Accounts payables		1,692	1,756
Employee-related obligations		526	685
Accrued expenses		1,851	1,780
Other current liabilities		739	933
Total current liabilities		12,089	13,164
Long-term liabilities:
Deferred income taxes		991	964
Other taxes and long-term liabilities		2,220	2,240
Senior notes and loans		22,288	22,731
Operating lease liabilities		441	479
Total long-term liabilities		25,940	26,414
Commitments and contingencies, see note 10
Total liabilities		38,029	39,579
Teva shareholders' equity:
Ordinary shares of NIS 0.10 par value per share; March 31, 2021 and December 31, 2020: authorized 2,495 million shares; issued 1,208 million shares and 1,202 million shares, respectively		57	57
Additional paid-in capital		27,474	27,443
Accumulated deficit		(10,869)	(10,946)
Accumulated other comprehensive loss		(2,534)	(2,399)
Treasury shares as of March 31, 2021 and December 31, 2020 — 106 million ordinary shares		(4,128)	(4,128)
Stockholders' equity attributable to Teva shareholders		10,000	10,026
Non-controlling interests		975	1,035
Total equity		10,975	11,061
Total liabilities and equity		$ 49,004	$ 50,640

[1] Accumulated goodwill impairment as of March 31, 2021 and December 31, 2020 was approximately $25.6 billion.